MREO News and Press, Mereo BioPharma Group From 05/23/23

LONDON, May 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases today announced that data from the Phase 2 “ASTRAEUS” trial of alvelestat fo...

2023-05-08 13:15:58 ET The U.K.-based biotech Mereo BioPharma ( NASDAQ: MREO ) announced Monday that the company regained compliance with the minimum bid price requirement under the Nasdaq Listing Rules. Mereo ( MREO ) said that the Nasdaq Stock Market officially notified ...

2023-05-05 16:20:22 ET Mereo BioPharma ( NASDAQ: MREO ) said it had received approval to transfer listing of its ADS from Nasdaq Global Market to Nasdaq Capital Market. The transfer was effective at the opening of business on May 3, 2023. The Nasdaq Capital Market oper...

LONDON, May 05, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that it has received approval from Listing Qualifications Department of th...

LONDON, April 13, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, and other members...

2023-03-28 16:41:07 ET Mereo BioPharma Group press release ( NASDAQ: MREO ): FY GAAP EPS of -£0.06. As of December 31, 2022, the Company had cash and short-term deposits of £56.3 million Net loss attributable to equity holders for the year ended December 31, ...

LONDON, March 28, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the year ended December 31, 2022 and provided ...

2023-03-21 09:01:38 ET Investing in penny stocks can be highly rewarding, but it also comes with significant risks. The high-risk, high-reward nature of penny stocks means potential for significant returns. But they can also lose their entire investment if the stock’s price drops...

Clear path forward with proposed single Phase 3 study evaluating alvelestat at the 240 mg dose level versus placebo at 12-18 months for potential full approval in both the U.S. and EU No additional confirmatory study required Company to host conference call today at 8:30am ET LONDON...

Summary Mereo and Ultragenyx are collaborating to develop setrusumab, a sclerostin inhibitor, for treating patients with Osteogenesis Imperfecta. ASTEROID Phase 2 trial showed that setrusumab improved bone markers and density, and strength but not patient-reported outcomes or fracture r...